Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab

Neurology

Volumn 76, Issue 5, 2011, Pages 432-437

  Pope, W B ^a,b   Xia, Q ^c   Paton, V E ^c   Das, A ^c   Hambleton, J ^c   Kim, H J ^a,b   Huo, J ^a,b   Brown, M S ^a,b   Goldin, J ^a,b   Cloughesy, T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MedQIA Imaging Core ^*  (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; IRINOTECAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEURORADIOLOGIST; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RADIOLOGIST; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 79951486845     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820a0a8a     Document Type: Article

References (14)

1. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48:347-356.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
3. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent gli-oblastoma. J Clin Oncol 2009;27:4733-4740.
4. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinote-can at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
5. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173-180.
6. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787.
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Be-vacizumab plus irinotecan in recurrent glioblastoma multi-forme. J Clin Oncol 2007;25:4722-4729. (Pubitemid 350086473)
8. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus iri-notecan. J Neurooncol 2009;91:329-336.
9. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glio-blastoma. Neurology 2009;73:1200-1206.
10. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of gli-oma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61: 6624-6628. (Pubitemid 32896475)
11. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
12. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2: 306-314.
13. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007;114:443-458. (Pubitemid 47521501)
14. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280. (Pubitemid 20195640)